Searched for
UNLOXCYT
Buy, Sell or Hold: Citi maintains buy on Eicher Motors; Goldman Sachs retains buy on Max HealthcareBrokerages maintain a positive outlook on select large-cap pharmaceutical, automobile, and healthcare stocks, citing strong growth prospect...- Sun Pharma sees steady FY27 growth, progresses $11.75 bn Organon integration dealSun Pharma anticipates strong growth in the coming years. The company expects a high single-digit increase in its overall sales by FY2027. ...
- Sun Pharma Q4 Preview: Can Unloxcyt and speciality drugs help pharma major deliver another strong quarter?Sun Pharma is expected to post double-digit revenue growth in Q4FY26, driven by strong performance across speciality drugs, domestic formul...
- Sun Pharma shares jump over 9% after firm announces $12 billion Organon acquisitionSun Pharmaceutical Industries' shares surged after announcing the $11.75 billion acquisition of US-based Organon & Co., a global leader in ...
- ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till dateUS company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...
- Sun Pharma shares tumble 4% as firm closes in on $12-billion Organon acquisition. What’s spooking investors?Shares of Sun Pharmaceutical Industries fell sharply after ET reported the company had submitted a $12-billion binding offer for Organon & ...
- Sun Pharma closes in on Organon buy, gets set for $12 billion binding bidSun Pharmaceutical Industries is nearing a $12 billion acquisition of Organon & Co, marking its most significant overseas expansion. Follow...
- Sun Pharma Q3 profit jumps 16% YoY as branded and innovative businesses drive growthSun Pharma announced strong third quarter results. Sales rose 15% to Rs 15,469 crore and net profit climbed 16% to Rs 3,368 crore. Growth w...
- Sun Pharma places non-binding offer for US-based Organon in its boldest global bet everSun Pharmaceutical Industries Ltd has submitted a non-binding offer to acquire US-based Organon for an all-cash deal, securing $10-14 billi...
- Sun Pharma looks to rise in US with $10 billion Organon buyIndia's largest drugmaker, Sun Pharma, is considering a major acquisition. The company is evaluating the purchase of US-based Organon, a sp...
- New launches and R&D pipeline bolster Sun Pharma's long-term growth outlookSun Pharma reported robust global specialty growth and resilient domestic sales in Q3, despite US generics headwinds. Recent product launch...
- Sun Pharma’s US innovative drug sales surpass generics for the first timeSun Pharma's U.S. innovative medicine sales have surpassed generics for the first time, driven by key products like Ilumya and Cequa. The l...
- Sun Pharma's US innovative drug sales surpass generics for first timeSun Pharma is open to expanding its US manufacturing capabilities in response to the Trump administration's 100% tariff on medicines. The c...
- Sun Pharma Q2 Preview: PAT may rise 2% YoY; Leqselvi spending to weigh on marginsSun Pharma is expected to report modest Q2 FY26 earnings growth, with PAT likely up 2% YoY and revenue rising 7%. Analysts cite Leqselvi la...
- New launches to drive Sun Pharma’s future growth; PAT may take a hit by tax surgeSun Pharma anticipates revenue growth for fiscal year 26, building on an 8% increase in fiscal year 25. However, increased spending on mark...
- Sun Pharma lines up $100 mn to commercialise niche products this fiscalSun Pharmaceutical Industries plans a USD 100 million investment to commercialize innovative products this fiscal year, focusing on its spe...
- I-Sec upgrades Sun Pharma to Buy, target price Rs 1,895ICICI Securities has upgraded Sun Pharmaceutical Industries to 'Buy' with a revised target price of Rs 1895. Sun Pharma, a leading company ...
- Stocks to buy today: IndusInd Bank gets a downgrade; Motilal Oswal sees over 20% upside in Sun PharmaNuvama has downgraded IndusInd Bank to "Reduce" citing concerns over internal derivative trades and management changes, while Antique remai...
- Sun Pharma shares in focus as co to acquire Checkpoint Therapeutics for $355 millionSun Pharmaceutical announced the acquisition of Nasdaq-listed Checkpoint Therapeutics, an immunotherapy and oncology company. The deal invo...
- Sun Pharmaceuticals to acquire Checkpoint Therapeutics for $355 mnSun Pharmaceuticals will acquire Checkpoint Therapeutics for $355 million, bringing the FDA-approved anti-PD-L1 treatment for advanced cuta...
Load More
